Six months of adjuvant trastuzumab treatment is noninferior to the standard of care (SoC) of 12 months in patients with HER2-positive early-stage

Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has a dismal prognosis. Due to the lack of targetable oestrogen, progesterone and HER2 receptors, there is a paucity of effective therapies, with PARP and PI3K inhibitors also failing to significantly improve overall survival (OS) in recent trials. 

While TNBC immunotherapy has recently experienced a setback with the withdrawal of atezolizumab following a lack of progression-free survival (PFS) or OS benefit in the IMpassion131 trial, results of the KEYNOTE-522 and KEYNOTE-355 trials re-affirm the transformative role of immunotherapy in this indication.

Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.

A combined regimen of ribociclib plus letrozole as first-line treatment provides a statistically significant and clinically meaningful overall survival (OS) benefit vs placebo plus letrozole in postmenopausal patients with hormone receptor–positive and HER2-negative advanced breast cancer (BC), results of the phase III MONALEESA-2 study have shown.